Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Abbott (ABT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Stocks to Buy Ahead of Q2 Earnings Next Week
by Nalak Das
We have narrowed our search to five companies that are set to declare second-quarter earnings results next week. These are: GPC, ABT, AN, SNA, PPG.
What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?
by Zacks Equity Research
The recent FDA approvals and growing customer demand for core therapeutic lines is likely to have driven Abbott's (ABT) Q2 performance.
ABT vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ABT vs. LMAT: Which Stock Is the Better Value Option?
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $107.50, moving +0.45% from the previous trading session.
AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AngioDynamics' (ANGO) fiscal fourth quarter's top line is likely to have been driven by strong demand for its products.
Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker
by Zacks Equity Research
Abbott (ABT) receives FDA approval for the AVEIR DR leadless pacemaker system, featuring the proprietary i2i technology.
Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $107.22 in the latest trading session, marking a -1.65% move from the prior day.
Abbott (ABT) Teams Up With the ADA to Evaluate CGM Systems
by Zacks Equity Research
Abbott (ABT) and ADA are going to offer personalized, therapeutic nutrition for diabetes people using CGM systems.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $107.79 in the latest trading session, marking a -0.66% move from the prior day.
Abbott (ABT) EPD Sales Aid Growth Amid Currency Headwind
by Zacks Equity Research
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here's How Much a $1000 Investment in Abbott Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.
Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.
Abbott (ABT) Just Overtook the 50-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Abbott (ABT) Stock Moves -0.42%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $106.25, marking a -0.42% move from the previous day.
Surmodics (SRDX) Rallies on FDA Approval for SurVeil DCB
by Zacks Equity Research
Surmodics' (SRDX) SurVeil DCB is indicated to treat percutaneous transluminal angioplasty in peripheral artery disease patients. Abbott will initiate commercialization of SurVeil DCB, per a deal with Surmodics.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $101.86, moving +0.45% from the previous trading session.
Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers
by Zacks Equity Research
Abbott (ABT) continues to make good progress in Nutrition, increasing manufacturing production and recovering market share in this business.
Top Stock Reports for Procter & Gamble, Bank of America & Abbott Laboratories
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Bank of America Corporation (BAC) and Abbott Laboratories (ABT).
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $101.66, marking a -0.94% move from the previous day.
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?